Navigation Links
SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
Date:9/12/2007

ISELIN, N.J., Sept. 12 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD.OB), today announced that it will host a symposium entitled "Post-Operative Adhesions in Cardiac Surgery: Challenges and Solutions" for surgeons attending next week's European Association for Cardio- Thoracic Surgery Annual Meeting in Geneva, Switzerland. The symposium will be chaired by Professor Stephen Westaby of the John Radcliffe Hospital in Oxford, United Kingdom and will include presentations by principal investigators who participated in US and European clinical trials for REPEL-CV(R) Adhesion Barrier, the company's novel bioresorbable film intended to reduce the formation of adhesions (scar tissue) in cardiac surgical procedures. Professor Westaby stated, "It is important to inform our surgeon colleagues that, with REPEL-CV, we now appear to a have way of reducing patient risks associated with the presence of adhesions during cardiac reoperations."

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion and drug delivery products based on its proprietary bioresorbable polymer technology.

Statements in this Press Release that are not statements of historical fact, including statements regarding indications of the timing or ability to achieve regulatory approval and market launch for REPEL-CV or the potential market size for REPEL-CV, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the Company's efforts to obtain and maintain required FDA and other regulatory approvals; (ii) potential inability to secure funding as and when needed to support the Company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Symposium will include venture capital "coaching"
2. Fusion 2006 symposium focuses on making IT work for businesses
3. Early Stage Symposium session will help emerging companies prepare for investors
4. Food microbiology symposium will mark 25 years
5. High interest forces delay in food safety symposium
6. Milwaukee to host inaugural Great Lakes Agro-Security Symposium
7. Fusion 2005 symposium aims to bring CIOs to the boardroom
8. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
9. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
10. Symposium examines the effect of race on genetics and disease
11. Belmont Report Commission reuniting for Medical College of Wisconsin Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
Breaking Biology Technology:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):